## UHS: Universal Health Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.4% below STRENGTH zone (4.0-10.0%); PEG 1.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($217.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Capital Fund Management S.A. Grows Holdings in Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251201T041039 | Bullish | Relevance: 100%
- Capital Fund Management S.A. increased its stake in Universal Health Services (NYSE:UHS) by 12.9% in Q2, acquiring an additional 10,754 shares to own a total of 94,086 shares valued at $17.04 million. This comes as UHS reported strong Q3 earnings, surpassing analyst expectations with an EPS of $5.69 and revenue of $4.50 billion. Despite recent analyst upgrades, the consensus rating for UHS remains a "Hold" with an average target price of $232.64.

**2. Distillate Capital Partners LLC Trims Position in Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251203T041039 | Somewhat-Bullish | Relevance: 100%
- Distillate Capital Partners LLC reduced its stake in Universal Health Services (NYSE:UHS) by 5.5% in Q2, selling 4,477 shares, though institutional ownership remains high at 86.05%. Despite this, several other institutions significantly increased their positions. Universal Health Services reported strong quarterly earnings, beating estimates, declared a quarterly dividend, and holds a consensus "Hold" rating with a target price of $232.64.

**3. Tenet Healthcare Soars 72% YTD: But is the Rally Out of Breath?**
- Source: TradingView | 20251201T182148 | Somewhat-Bullish | Relevance: 72%
- Tenet Healthcare (THC) has seen an impressive 71.8% year-to-date gain, outperforming both its peers and the S&P 500, driven by strong demand for hospital services and strategic expansion in ambulatory care. The company's updated 2025 guidance and favorable analyst estimates reflect continued confidence, despite a somewhat stretched valuation and potential policy-related reimbursement risks. While there's still upside, its current Zacks Rank #3 (Hold) suggests a more balanced outlook compared to earlier in the year.

**4. HCAâ€™s Cash Machine Looks Cheap After A Healthy Run**
- Source: Finimize | 20251203T145120 | Neutral | Relevance: 71%
- HCA Healthcare, the largest for-profit hospital operator in the U.S., has shown strong recent performance with a 56.6% total return over 12 months and raised full-year guidance for 2025. Despite policy risks and labor cost inflation, its robust cash generation, strong margins, and perceived valuation discount make it an appealing opportunity for long-term investors, though the stock carries risks associated with leverage and regulatory uncertainty.

**5. Tenet Healthcare Soars 72% YTD: But is the Rally Out of Breath?**
- Source: Finviz | 20251201T162300 | Neutral | Relevance: 70%
- Tenet Healthcare has seen a significant 71.8% year-to-date gain, outperforming peers and the S&P 500, driven by strong demand for hospital services, expansion in ambulatory care, and positive financial guidance. Despite its strong performance, the article highlights potential risks due to a stretched valuation and policy-related reimbursement concerns, leading to a Zacks Rank #3 (Hold).

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Guggenheim | $274 | $253 | +8% |
| 2025-11-13 | Wells Fargo | $259 | $249 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Guggenheim | main | Buy |
| 2025-11-13 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($11.07M) |
| Sells | 3 ($30.51M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-3.4%)
- First Eagle Investme: 8.4% (+0.0%)
- Blackrock Inc.: 8.0% (-11.9%)
- State Street Corpora: 4.7% (-3.1%)
- FMR, LLC: 3.8% (+0.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $31M sold (3 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.87 elevated, pricing in significant growth expectations. Analyst sentiment positive (2 raises, avg +6%). Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.5B |
| Beta | 1.27 |
| 52W Range | $152.33 - $246.33 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.87 |
| Forward P/E | 9.8 |
| Current P/E | 10.6 |
| YoY Growth | 8.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 6.4% to -2.4% (-8.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.22x) but short-term weakness (below SMA20). RSI neutral at 52. OFD pattern: -F0N (Breakdown).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.35% (CS: 27) | Weak |
| RSI_14 | 52.5 | Neutral |
| MACD Histogram | -0.48 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 1.059x | Above |
| vs SMA200 | 1.220x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $230.15
- **Stop Loss:** $217.09 (5.7% risk)
- **Target:** $243.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 72
- **Position Value:** $16,570.80
- **Portfolio %:** 16.57%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-25 (Est: $5.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.95 | $5.69 | +14.9% |
| 2025Q2 | $4.96 | $5.35 | +8.0% |
| 2025Q1 | $4.36 | $4.84 | +11.1% |
| 2024Q4 | $4.18 | $4.92 | +17.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*